Adding glutamine to standard chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding L-glutamine (an amino acid supplement) to the usual chemotherapy for advanced pancreatic cancer can help the treatment work better. It aims to see if the combination is safe and effective for people who have not had chemo for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that cannot be removed with surgery, or it has come back after treatment.
- You are at least 18 years old.
- You are able to do most of your daily activities (ECOG performance status 0-2 or Karnofsky 60% or higher).
- You have not had chemotherapy for your advanced disease before, though prior treatment before a recurrence is allowed if it ended at least 6 months ago.
- You are willing to provide blood, stool, and tissue samples as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests whether adding astragalus, an herbal supplement, to the standard chemotherapy drug gemcitabine before surgery can improve outcomes for people with pancreatic cancer. It is a phase 2 study designed to see if the combination is safe and effective.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.